The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Everolimus (RAD) as treatment in breast cancer patients with bone metastases only: Results of the phase II RADAR study.
Nicolai Maass
No relevant relationships to disclose
Nadia Harbeck
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Christoph Mundhenke
Honoraria - Novartis
Christian A. Lerchenmuller
No relevant relationships to disclose
Jana Barinoff
No relevant relationships to disclose
Hans-Joachim Lueck
Consultant or Advisory Role - Celgene; Roche; Sanofi
Honoraria - Celgene; Eisai; GlaxoSmithKline; Roche
Johannes Ettl
No relevant relationships to disclose
Bahriye Aktas
No relevant relationships to disclose
Sherko Kuemmel
Honoraria - GlaxoSmithKline
Siegfried Roesel
No relevant relationships to disclose
Steffen Wagner
No relevant relationships to disclose
Lothar Müller
No relevant relationships to disclose
Joachim Bischoff
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Kristina Luebbe
No relevant relationships to disclose
Kathrin Schwedler
No relevant relationships to disclose
Marcus Schmidt
No relevant relationships to disclose
Dirk Bauerschlag
No relevant relationships to disclose
Valentina Nekljudova
No relevant relationships to disclose
Sibylle Loibl
Other Remuneration - Novartis
Gunter Von Minckwitz
Research Funding - Novartis